Tobias Kanacher, Ph.D.

Senior Consultant

Bio

  • Joined Pharmetheus in 2019, actively working in client projects
  • Expertise includes physiological based pharmacokinetic modeling (PBPK), pediatrics, and MIDD in therapeutic areas such as oncology, women’s health, and cardiovascular diseases
  • Previously worked as Consultant Modeling and Simulation at SGS Exprimo NV, Belgium, where he provided advice and hands-on application of pharmacometric approaches to support drug development in various therapeutic areas, as Systems Pharmacology Expert at Bayer / Bayer Technology Services GmbH, Germany, PBPK Expert in Exploratory ADME at Nycomed: a Takeda Company, Germany, Laboratory Team Leader in Exploratory ADME at Altana Pharma AG / Nycomed Gmbh, Germany, and Laboratory Team and Target-Project Leader in Preclinical Research at Altana Pharma AG, Germany
  • Pharmacist Licensure (1999) from the University Marburg, Germany, and Ph.D. in Pharmaceutical Biochemistry (2003) from the University Tübingen, Germany
LinkedInGoogle Scholar

Pharmetheus affiliated publications

A Physiologically Based Pharmacokinetic Model of Atorvastatin Acid Predicting CYP3A4 and OATP1B Drug–Drug InteractionsDevelopment of a Physiologically-Based Pharmacokinetic Model for Coproporphyrin I (CP-I) Using the Open Systems Pharmacology Software Suite (PK-Sim and MoBi) for assessment of OATP1B-based DDIsA Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine